CD8A and neoplasm: Following on from our studies, Moral et al. report that ILC2s within pancreatic tumours express the checkpoint inhibitor PD-1 and that upon treatment with anti-PD-1 immunotherapy, these ILC2s expand, become activated, and augment anti-tumour immunity by priming CD8+ T cells66.